argenx is a biotechnology company that develops antibody-based therapies for severe autoimmune diseases, including its FcRn-blocker Vyvgart.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Steve Cohen / Point72 | 76 | Added +545% | 45,783 | $42,476,094 | 0.0% |
| Bridgewater | 56 | Added +61% | 1,958 | $1,816,574 | 0.0% |
| Ancora | 40 | Trimmed -25% | 6 | $5,567 | 0.0% |
| Trade date | Who | Type | Amount | |
|---|---|---|---|---|
| 2026-03-30 | Alan Armstrong senate | BUY | $1,001 - $15,000 | PTR |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-09-24.